---
title: Medical Device Regulation in Brazil (ANVISA): Entering South America
description: How EU MedTech startups enter Brazil via ANVISA: classification, BRH sponsor, BPF inspection, MDSAP route, registration timelines, and Portuguese labelling.
authors: Tibor Zechmeister, Felix Lenhard
category: FDA & International Market Access
primary_keyword: Brazil ANVISA medical device
canonical_url: https://zechmeister-solutions.com/en/blog/brazil-anvisa-medical-device
source: zechmeister-solutions.com
license: All rights reserved. Content may be cited with attribution and a link to the canonical URL.
---

# Medical Device Regulation in Brazil (ANVISA): Entering South America

*By Tibor Zechmeister (EU MDR Expert, Notified Body Lead Auditor) and Felix Lenhard.*

> **Brazil regulates medical devices through ANVISA (Agência Nacional de Vigilância Sanitária) under a framework of Resoluções da Diretoria Colegiada (RDC). Foreign manufacturers cannot register devices themselves — they must appoint a Brazilian Registration Holder (BRH) who holds the registration, handles customs, and carries post-market obligations. ANVISA classifies devices Class I to IV and accepts MDSAP as evidence for the BPF (Good Manufacturing Practices) inspection requirement, making MDSAP the single highest-leverage decision for EU startups entering Brazil.**

**By Tibor Zechmeister and Felix Lenhard.**

## TL;DR
- Brazil's medical device framework sits in ANVISA's RDC series — the primary instruments being the current RDC on medical device classification, registration, and BPF (Boas Práticas de Fabricação, Good Manufacturing Practices) .
- Classification uses Class I to IV, risk-based rules similar in logic to the EU system but with specific Brazilian interpretations.
- A foreign manufacturer must appoint a Brazilian Registration Holder (Detentor do Registro) — a Brazilian legal entity authorised by ANVISA to hold the registration.
- BPF compliance is demonstrated via on-site ANVISA inspection OR, more commonly for foreign manufacturers, via a valid MDSAP certificate, which ANVISA accepts as equivalent.
- All labelling, instructions for use, and patient-facing materials must be in Brazilian Portuguese.
- Registration timelines vary dramatically by class: Class I and II are notification-based and fast; Class III and IV are registration-based and historically slower, though recent ANVISA reforms have shortened timelines.

## Why Brazil matters for EU MedTech founders

Brazil is the largest medical device market in South America by a wide margin, with a population above 200 million, a growing private healthcare sector, and a public health system (SUS) that is a real procurement channel for devices. For EU startups with a working CE certificate and ambitions beyond the EU, Brazil is the natural South American beachhead — everything else in the region is smaller and, in many cases, references Brazilian registration as a starting point.

Brazil is also the market where founders most often confuse "close enough" with "the same". ANVISA's framework is rigorous, specific, and unforgiving of sloppy documentation. The language barrier is real — not a formality. The BRH dependency is structural — you do not own your own registration in Brazil, your BRH does, and that changes the negotiating dynamic with distributors in ways EU founders rarely anticipate.

Good news: if you already hold MDSAP (because you are entering Canada, Australia, Japan, or the US), Brazil becomes dramatically cheaper. ANVISA is a founding MDSAP regulatory authority. That is the single biggest lever an EU startup has.

## What the Brazilian framework actually says

The regulatory architecture:

- **ANVISA (Agência Nacional de Vigilância Sanitária)** — federal health surveillance agency, created by Law 9.782/1999, with authority over medical devices, drugs, food, and other health-regulated products.
- **RDC (Resolução da Diretoria Colegiada)** series — the operational regulations. Key ones for medical devices cover classification rules, registration and notification procedures, BPF requirements, labelling, post-market vigilance, and changes to registrations .
- **BPF (Boas Práticas de Fabricação)** — Brazilian Good Manufacturing Practices. Compliance is demonstrated either by direct ANVISA inspection of the manufacturing site or, for foreign manufacturers, by a valid MDSAP certificate accepted as equivalent.

Two principal pathways exist based on class:

- **Notificação (Notification)** — for lower-risk classes (Class I and Class II under current rules). Faster, lighter documentation burden, effectively self-declared with ANVISA acknowledgment.
- **Registro (Registration)** — for higher-risk classes (Class III and Class IV). Full technical dossier review by ANVISA, stricter documentation, longer timelines.

The Brazilian Registration Holder (BRH) — legally "Detentor do Registro" — is the linchpin. The foreign manufacturer does not appear on the Brazilian registration as the holder. The BRH does. The BRH must be a Brazilian legal entity authorised to import medical devices, with ANVISA authorisation (Autorização de Funcionamento de Empresa, AFE). The BRH carries vigilance reporting obligations, responds to ANVISA inspections, and physically imports the devices.

## A worked example: a Class III device from Munich

Imagine a German SME with a Class III cardiovascular device. They hold:

- MDR Annex IX certificate from their EU notified body.
- EN ISO 13485:2016+A11:2021 certificate issued by the same notified body, which is also an MDSAP Auditing Organisation.
- Full MDR technical documentation.
- A distributor relationship in Brazil that predates their ANVISA plans.

To enter Brazil:

1. **Decide the BRH question first.** They have three options:
   - Use the existing distributor as BRH. Cheapest, but ties the registration to one channel.
   - Appoint a neutral regulatory services firm as BRH. More control, higher annual cost.
   - Create a Brazilian subsidiary. Only worth it at scale.
2. **Commission (or schedule) an MDSAP audit** that explicitly covers Brazil as one of the MDSAP member jurisdictions. This avoids a direct ANVISA inspection of the Munich site, which historically has been a long queue and a significant cost.
3. **Classify the device under the current ANVISA rules.** A Class III under MDR typically maps to Class III or IV in Brazil — mapping must be formally documented under the current Brazilian classification RDC.
4. **Prepare the registration dossier in Portuguese.** This includes technical documentation, clinical evidence summaries, labels, instructions for use, risk management summary, and BPF evidence (MDSAP certificate + supporting documents).
5. **Submit via the BRH** to ANVISA through the official petition system.
6. **Respond to ANVISA exigências** (technical questions). Response quality and speed dominate total timeline.
7. **Prepare for the publication of the registration** in the Diário Oficial da União, at which point the device can legally be imported and sold.

Realistic timelines for a Class III device with MDSAP already in place and a competent BRH: 9–18 months from submission to published registration, depending on ANVISA workload and the quality of responses to exigências. Without MDSAP, add 12+ months for the BPF inspection path.

## The Subtract to Ship playbook for Brazil

**Step 1 — Do not enter Brazil without MDSAP.** The economics are brutal without it. A direct ANVISA BPF inspection of a European manufacturing site is expensive, slow to schedule, and procedurally demanding. MDSAP replaces this and is the single leverage point for EU startups. If you cannot commit to MDSAP, defer Brazil.

**Step 2 — Decide the BRH structure before you talk to distributors.** This is a sequencing discipline. Once a Brazilian distributor is in the middle of a deal, they will want to be your BRH. That may or may not be the right call — but it should be a deliberate decision made on regulatory grounds, not a concession to close a commercial deal.

**Step 3 — Translate once, well.** Brazilian Portuguese labels, IFUs, and patient materials are a known scope item. Budget for professional translation by a translator with medical device experience. Do not use EU Portuguese translators without specific Brazilian medical experience — the terminology and regulatory register differ.

**Step 4 — Write the classification rationale as a standalone document.** ANVISA inspectors and reviewers expect a clear classification justification under the current Brazilian RDC. Do not cite "Class III per MDR Rule 8" — cite the applicable Brazilian rule explicitly.

**Step 5 — Reuse your MDR technical file, mapped to ANVISA's expectations.** ANVISA will not accept your MDR technical file wholesale, but the underlying evidence — CER, risk management, verification/validation — is almost entirely reusable. Build a cross-reference table from the ANVISA dossier requirements to your existing MDR file sections.

**Step 6 — Plan the change control chain.** Every change to a registered device must be managed through ANVISA change procedures, filed by the BRH. Your internal change control must include a "Brazil impact" check that triggers BRH notification well before changes go live in the EU.

**Step 7 — Build post-market surveillance into the BRH contract.** Brazilian vigilance reporting timelines and formats are specific. The BRH is the legal reporter to ANVISA, but you supply the data. The handoff must be spelled out in the agreement — who reports what, to whom, by when — or you will miss deadlines.

## Reality Check

1. Have you confirmed that MDSAP is part of your regulatory strategy, and if so, have you scheduled or completed an MDSAP audit scope that explicitly covers Brazil?
2. Have you decided on a BRH structure — distributor-as-BRH, neutral regulatory firm, or own subsidiary — and documented the reasoning?
3. Have you mapped your device class under the current Brazilian classification RDC and written down the justification?
4. Do you have Brazilian Portuguese labels, IFUs, and patient materials prepared by a translator with medical device experience, not just any Portuguese translator?
5. Have you budgeted the registration fees (which scale by class), BRH annual fees, and translation costs into a 3-year operating model?
6. Does your change control process include a Brazil impact check that triggers BRH notification before device changes reach the EU market?
7. Have you defined, in writing, the vigilance data handoff between your team and the BRH, including timelines that meet Brazilian reporting requirements?
8. If your device is higher risk, have you mapped the ANVISA registration pathway (as opposed to the lighter notification pathway) and budgeted realistic 12–18 month timelines?

If more than two answers are "no", Brazil entry is not ready to start.

## Frequently Asked Questions

**Do I need to be physically present in Brazil to sell a medical device?**
No, but you cannot be the legal holder of the Brazilian registration. You must appoint a Brazilian Registration Holder, who must be a Brazilian legal entity with ANVISA's AFE authorisation. The BRH is your regulatory face in Brazil.

**Is MDSAP really accepted by ANVISA in place of a BPF inspection?**
Yes. ANVISA is a founding MDSAP regulatory authority and accepts valid MDSAP certificates as evidence of BPF compliance, removing the need for a direct on-site ANVISA inspection of the foreign manufacturing site. This is the primary reason MDSAP is high-leverage for EU startups entering Brazil.

**How long does Class III registration really take?**
With MDSAP in place and a competent BRH, 9–18 months is a realistic band from submission to published registration. Without MDSAP, expect the BPF inspection alone to add a year or more. Without an experienced BRH, expect exigência response cycles to stretch the timeline further.

**Can my CE mark substitute for ANVISA registration?**
No. CE is not a substitute for Brazilian registration. ANVISA runs its own registration system. Your CE evidence is useful supporting material in the dossier, but it does not bypass the ANVISA process.

**Does the BRH own my registration forever?**
Effectively yes, unless you plan for portability. The registration is held in the BRH's name. Transferring it to another BRH is possible but administratively painful. This is why the BRH choice matters more than the distributor choice.

**What are the language requirements?**
Brazilian Portuguese is mandatory for labels, IFUs, patient information, promotional material, and all submissions to ANVISA. English or other-language labels are not acceptable for commercial distribution.

## Related reading
- [MDSAP: Single Audit, Multiple Markets](/blog/mdsap-single-audit-multiple-markets) — Brazil is one of the five MDSAP member jurisdictions, which makes MDSAP the single biggest leverage point for EU startups entering the country.
- [International expansion sequencing](/blog/international-expansion-sequencing) — where Brazil fits in a sensible global rollout order after CE mark.
- [Prioritize international markets for MedTech](/blog/prioritize-international-markets-medtech) — decision framework for ranking Brazil against Australia, Canada, US, and Asia.
- [IMDRF and global harmonization for startups](/blog/imdrf-global-harmonization-startups) — the harmonization context that underpins MDSAP acceptance in Brazil.
- [International market access checklist 2027](/blog/international-market-access-checklist-2027) — master checklist that ties Brazil into an integrated multi-market rollout.

## Sources
1. ANVISA (Agência Nacional de Vigilância Sanitária) Resoluções da Diretoria Colegiada (RDC) on medical device classification, registration, labelling, BPF, and post-market vigilance .
2. Lei 9.782/1999 (Federative Republic of Brazil) — establishes ANVISA and the Sistema Nacional de Vigilância Sanitária.
3. Regulation (EU) 2017/745 on medical devices, consolidated text. Article 10, Annex IX.
4. EN ISO 13485:2016+A11:2021 — Medical devices — Quality management systems — Requirements for regulatory purposes.
5. IMDRF Medical Device Single Audit Program (MDSAP) regulatory authority framework documents.

---

*This post is part of the [FDA & International Market Access](https://zechmeister-solutions.com/en/blog/category/fda-international) cluster in the [Subtract to Ship: MDR Blog](https://zechmeister-solutions.com/en/blog). For EU MDR certification consulting, see [zechmeister-solutions.com](https://zechmeister-solutions.com).*